Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
For Acadia’s Pimavanserin, The Second Time Is The Charm
Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in its original Phase III trial.
For Acadia’s Pimavanserin, The Second Time Is The Charm
Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in an original Phase III trial.
Hikma To Divest Phenytoin, Promethazine Injectables To Acquire Baxter Business
X-Gen Pharmaceuticals will purchase the products as part of the FTC-mandated divesture. Without the transaction, Hospira would have been the only other company that sold the two drugs once Hikma acquired Baxter's entire generic injectable business.